EarlyCDT®-Lung is a simple blood test which is ordered by a healthcare provider to aid in the risk assessment and early detection of lung cancer.
EarlyCDT-Lung detects the body’s immune response, in the form of autoantibodies (or immuno-biomarkers), to antigens produced by solid-tumour cells. It aids in risk assessment and early cancer detection by using a panel of tumour antigens that are selected for their involvement in the development of lung cancer.
In healthy individuals, the immune system does not produce antibodies against normal tissue antigens. However, when cancer develops, cancer cells produce proteins with antigens that are abnormal or in some way modified from those found in normal tissue.
The immune system detects these antigens and reacts by producing an abundance of autoantibodies that circulate in the bloodstream. As these autoantibodies form and circulate in the body at all stages of the disease including during Stages I and II, the earliest stages of lung cancer, their measurement signifies the presence of cancerous cells.
Used in conjunction with diagnostic imaging EarlyCDT-Lung has the potential to aid in the identification of lung cancer at a very early stage when treatment can be most successful.
Please see the What is EarlyCDT-Lung section to understand more about how the test works and understand the Benefits of Early Detection of lung cancer.
If you want to know more about your risk with regards to lung cancer then go to the Risk calculator page.
For more information about how to get the test in the UK, please see the Test Providers section.